The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Parfenov A.I.

GBUZ "Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr" Departamenta zdravookhraneniia Moskvy

Crohn's disease: on the occasion of the 80th anniversary of description

Authors:

Parfenov A.I.

More about the authors

Journal: Therapeutic Archive. 2013;85(8): 35‑42

Read: 12308 times


To cite this article:

Parfenov AI. Crohn's disease: on the occasion of the 80th anniversary of description. Therapeutic Archive. 2013;85(8):35‑42. (In Russ.)

Recommended articles:
Algo­rithms for the diagnosis of autoimmune ence­phalitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):12-22
Current global trends in the epidemiology of inflammatory bowel diseases. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):104-117

References:

  1. Crohn's Disease and Ulcerative Colitis - From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Baumgart DC, ed. New York: Springer 2012.
  2. Lee A., Griffiths .A., Parab R.S. et al. Association of Mycobacterium avium subspecies paratuberculosis with Crohn Disease in pediatric patients. J Pediatr Gastroenterol Nutr 2011; 52: 170-174.
  3. Nakase H., Tamaki H., Matsuura M. et al. Involvement of mycobacterium avium subspecies paratuberculosis in TNF-α production from macrophage: Possible link between MAP and immune response in Crohn's disease. Inflammatory bowel diseases. 2011; 17 (11): E140-E142.
  4. Barreau F., Madre C., Meinzer U. et al. Nod2 regulates the host response towards microfl ora by modulating T cell function and epithelial permeability in mouse Peyer's patches. Gut 2010; 59: 207-217.
  5. Baumgart D., Sandborn W. Crohn's Disease. The Lancet 2012; 380 (9853): 1590-1605.
  6. Colombel J.F., Sandborn W.J., Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
  7. Cosnes J., Cattan S., Blain A. et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
  8. Al-Hawary M., Zimmermann E.M. A New Look at Crohn's Disease. Novel Imaging Techniques. Curr Opin Gastroenterol 2012; 28 (4): 334-340.
  9. Ferrante M., Henckaerts L., Joossens M. et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56 (10): 1394-1403.
  10. Seow C.H., Stempak J.M., Xu W. et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009; 104 (6): 1426-1434.
  11. Perencevich M., Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 (7): 651-664.
  12. Khan K., Ullman T., Ford A. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106 (4): 661-673.
  13. Dignass A., Van Assche G., Lindsay J.O. et al. The second European evidence-based consensus on the diagnosis and management of Crohn's Disease: current management. J. Crohn's Colitis.2010; 4: 28-62.
  14. Gordon M., Naidoo K., Thomas A.G., Akobeng A.K. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011; 1: CD008414.
  15. Seow C.H., Benchimol E.I., Griffiths A.M. et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; CD000296.
  16. Dignass A., Van Assche G., Lindsay J.O. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J. Crohns Colitis 2010; 4: 28-62.
  17. Peyrin-Biroulet L., Deltenre P., Ardizzone S. et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-2096.
  18. Lin M.V., Blonski W., Lichtenstein G.R., Present D.H. What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev Gastroenterol Hepatol 2010; 4: 167-180.
  19. Knyazev O.V., Parfenov A.I., Ruchkina I.N. i dr. Novye vozmozhnosti preodoleniya vtorichnoi neeffektivnosti antitsitokinovoi terapii u bol'nykh vospalitel'nymi zabolevaniyami kishechnika. Ter arkh 2013; 2: 57-60.
  20. Neurath M.F., Travis S.P.L. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61 (11): 1619-1635.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.